These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1274 related items for PubMed ID: 15282532

  • 1. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM, Waller EK.
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [Abstract] [Full Text] [Related]

  • 2. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [Abstract] [Full Text] [Related]

  • 3. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD, Becker EE, LaBelle JL, Truitt RL.
    J Immunol; 1999 Dec 15; 163(12):6479-87. PubMed ID: 10586039
    [Abstract] [Full Text] [Related]

  • 4. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z, Shatry A, Deyev V, Podack E, Mammolenti M, Blazar BR, Yagita H, Levy RB.
    Biol Blood Marrow Transplant; 2005 Aug 15; 11(8):576-86. PubMed ID: 16041307
    [Abstract] [Full Text] [Related]

  • 5. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
    Hossain MS, Roback JD, Lezhava L, Hillyer CD, Waller EK.
    Biol Blood Marrow Transplant; 2005 Mar 15; 11(3):169-80. PubMed ID: 15744235
    [Abstract] [Full Text] [Related]

  • 6. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 7. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Sep 15; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 8. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS, Riley R, Hamilton BL, Paupe J, Perez D, Levy RB.
    Bone Marrow Transplant; 1994 Nov 15; 14(5):725-35. PubMed ID: 7889005
    [Abstract] [Full Text] [Related]

  • 9. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr 15; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 10. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D, García-López J, Sureda A, Canals C, Ferra C, Cancelas JA, Berlanga JJ, Brunet S, Boqué C, Picón M, Torrico C, Amill B, Martino R, Martínez C, Martín-Henao G, Domingo-Albós A, Grañena A.
    Bone Marrow Transplant; 1997 Dec 15; 20(11):945-52. PubMed ID: 9422473
    [Abstract] [Full Text] [Related]

  • 11. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD, Becker EE, Truitt RL.
    Biol Blood Marrow Transplant; 1999 Dec 15; 5(3):123-32. PubMed ID: 10392958
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
    Abraham VS, Sachs DH, Sykes M.
    J Immunol; 1992 Jun 15; 148(12):3746-52. PubMed ID: 1534824
    [Abstract] [Full Text] [Related]

  • 13. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B, Li DP, Xu KL, Pan XY.
    Chin Med J (Engl); 2005 Mar 20; 118(6):474-9. PubMed ID: 15788128
    [Abstract] [Full Text] [Related]

  • 14. Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.
    Ewing P, Miklos S, Olkiewicz KM, Müller G, Andreesen R, Holler E, Cooke KR, Hildebrandt GC.
    Exp Hematol; 2007 Jan 20; 35(1):155-63. PubMed ID: 17198884
    [Abstract] [Full Text] [Related]

  • 15. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug 20; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 16. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM, Gorechlad J, Larsen CP, Waller EK.
    Biol Blood Marrow Transplant; 2006 Dec 20; 12(12):1239-49. PubMed ID: 17162205
    [Abstract] [Full Text] [Related]

  • 17. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
    Moyer JS, Maine G, Mulé JJ.
    Biol Blood Marrow Transplant; 2006 Oct 20; 12(10):1010-9. PubMed ID: 17084367
    [Abstract] [Full Text] [Related]

  • 18. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 20; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 19. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR, Taylor PA, Fitzsimmons WE, Vallera DA.
    J Immunol; 1994 Aug 15; 153(4):1836-46. PubMed ID: 7519216
    [Abstract] [Full Text] [Related]

  • 20. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 15; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.